Tofacitinib in Juvenile Idiopathic Arthritis

Efficacy of Tofacitinib in Patients With Juvenile Idiopathic Arthritis: A Study Based on Real-world Clinical Practice Data.

This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.

Inclusion criteria:

Diagnosis of juvenile idiopathic arthritis (JIA) documented in the medical record by the treating rheumatologist.

Documentation in the medical record of the medical indication for tofacitinib treatment, with a diagnostic justification related to JIA.

Age under 18 years at the time of the treatment indication with tofacitinib.

Exclusion criteria:

Participants diagnosed with any of the following conditions:

Reactive arthritis

Arthritis associated with inflammatory bowel disease

Arthritis associated with another autoimmune disease